American Vietnamese Biotech Incorporation (HNX:AMV)
Vietnam · Delayed Price · Currency is VND 1,200.00
-100.00 (-7.69%)
At close: Aug 12, 2026
HNX:AMV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 102,406 | 159,667 | 310,355 | 196,570 | 281,818 | 223,843 | |
Revenue Growth | -69.04% | -48.55% | 57.88% | -30.25% | 25.90% | 38.66% |
Cost of Revenue | 90,195 | 137,823 | 279,093 | 146,978 | 202,869 | 110,149 |
Gross Profit | 12,211 | 21,844 | 31,261 | 49,592 | 78,949 | 113,694 |
Selling, General & Admin | 37,578 | 65,888 | 35,574 | 17,122 | 15,478 | 14,028 |
Operating Expenses | 41,848 | 65,888 | 35,574 | 17,122 | 15,478 | 14,028 |
Operating Income | -29,637 | -44,043 | -4,313 | 32,471 | 63,472 | 99,666 |
Interest Expense | -33,118 | -18,655 | -19,650 | -23,353 | -20,309 | -18,124 |
Interest & Investment Income | 2,658 | 2,405 | 1,844 | 1,153 | 2,511 | 3,482 |
Earnings From Equity Investments | -4,468 | -6,675 | -1,886 | - | - | - |
Currency Exchange Gain (Loss) | - | - | -460.96 | 1,164 | - | - |
Other Non Operating Income (Expenses) | -6,263 | -6,252 | -180.03 | -1,625 | 10,812 | -3,417 |
EBT Excluding Unusual Items | -70,827 | -73,221 | -24,646 | 9,809 | 56,487 | 81,608 |
Gain (Loss) on Sale of Investments | -1,240 | -1,240 | - | - | - | - |
Gain (Loss) on Sale of Assets | 736.39 | 736.39 | 11,209 | 1,641 | - | - |
Other Unusual Items | 22.87 | 22.87 | 1,947 | - | - | - |
Pretax Income | -71,308 | -73,701 | -11,491 | 11,450 | 56,487 | 81,608 |
Income Tax Expense | 795.35 | 795.35 | 1,575 | 718.26 | 1,316 | - |
Earnings From Continuing Operations | -72,103 | -74,496 | -13,065 | 10,732 | 55,171 | 81,608 |
Minority Interest in Earnings | 936.66 | 1,859 | 1,874 | -47.13 | -1,239 | 631.67 |
Net Income | -71,166 | -72,637 | -11,191 | 10,685 | 53,931 | 82,240 |
Net Income to Common | -71,166 | -72,637 | -11,191 | 10,685 | 53,931 | 82,240 |
Net Income Growth | - | - | - | -80.19% | -34.42% | 5.36% |
Shares Outstanding (Basic) | 131 | 131 | 131 | 131 | 107 | 84 |
Shares Outstanding (Diluted) | 131 | 131 | 131 | 131 | 107 | 84 |
Shares Change | 0.01% | - | - | 22.04% | 27.63% | 58.37% |
EPS (Basic) | -543.03 | -554.04 | -85.36 | 81.50 | 502.00 | 977.00 |
EPS (Diluted) | -543.03 | -554.04 | -85.36 | 81.00 | 502.00 | 977.00 |
EPS Growth | - | - | - | -83.86% | -48.62% | -33.47% |
Free Cash Flow | 40,749 | 372,344 | 628,530 | -144,792 | -347,688 | -510,894 |
Free Cash Flow Per Share | 310.93 | 2840.03 | 4794.07 | -1104.39 | -3236.32 | -6069.36 |
Gross Margin | 11.92% | 13.68% | 10.07% | 25.23% | 28.01% | 50.79% |
Operating Margin | -28.94% | -27.58% | -1.39% | 16.52% | 22.52% | 44.52% |
Profit Margin | -69.49% | -45.49% | -3.61% | 5.44% | 19.14% | 36.74% |
Free Cash Flow Margin | 39.79% | 233.20% | 202.52% | -73.66% | -123.37% | -228.24% |
EBITDA | -11,437 | -21,622 | 19,632 | 54,302 | 83,871 | 115,543 |
EBITDA Margin | -11.17% | -13.54% | 6.33% | 27.63% | 29.76% | 51.62% |
D&A For EBITDA | 18,199 | 22,421 | 23,945 | 21,832 | 20,399 | 15,877 |
EBIT | -29,637 | -44,043 | -4,313 | 32,471 | 63,472 | 99,666 |
EBIT Margin | -28.94% | -27.58% | -1.39% | 16.52% | 22.52% | 44.52% |
Effective Tax Rate | - | - | - | 6.27% | 2.33% | - |
Revenue as Reported | 102,406 | 159,667 | 310,355 | 196,570 | 281,818 | 223,843 |